We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ISC-hpNSC
Previous Study | Return to List | Next Study

A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease

This study is currently recruiting participants.
Verified July 2017 by Cyto Therapeutics Pty Limited
Sponsor:
ClinicalTrials.gov Identifier:
NCT02452723
First Posted: May 25, 2015
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cyto Therapeutics Pty Limited
  Purpose
This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease. All patients will receive the therapy, which consists of human neural stem cells. Three dose levels will be examined in the study.

Condition Intervention Phase
Parkinson Disease Biological: ISC-hpNSC Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Cyto Therapeutics Pty Limited:

Primary Outcome Measures:
  • Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, related TEAEs, severe TEAEs [ Time Frame: 12 month ]

Secondary Outcome Measures:
  • Change in UPDRS score from baseline [ Time Frame: Baseline and 12 months ]
  • Proportion of patients with improvement defined as any reduction in UPDRS motor score [ Time Frame: 12 months ]

Estimated Enrollment: 12
Study Start Date: March 2016
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ISC-hpNSC Biological: ISC-hpNSC

Detailed Description:

ISC-hpNSC is a cellular therapeutic consisting of human parthenogenetic neural stem cells (hpNSC). ISC-hpNSC will be injected intracerebrally to the striatum and substantia nigra of patients with Parkinson's disease (PD).

The study will enroll 4 patients for cell injection at each of three different doses. A total of 12 patients with moderate to severe PD will be treated. Each patient receives a single dose. The main objective of the study is to evaluate the safety of the cell transplantation.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent form (ICF) indicating the patient has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts
  • Patient diagnosed with idiopathic PD of ≤ 13 years duration, as defined by the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria
  • Outpatients (male and female) 30 - 70 years old. Females must be of non-child bearing potential, or with a negative pregnancy test and not breast-feeding
  • Patients receiving a stable dose of levodopa for at least 3 months with the expectation that the treatment will remain unchanged throughout the course of the patient's participation in the trial
  • Patients receiving an anti-parkinsonian treatment at a stable dose for at least 3 months with the expectation that the treatment will remain unchanged throughout the course of the patient's participation in the trial
  • Hoehn and Yahr stage II-IV during "ON" time
  • Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) in the "OFF" state ≤ 49
  • Positive dopaminergic response of ≥ 33% decrease in UPDRS motor scores between "OFF" and "ON" states at screening, and unequivocal clinical off periods
  • Patient is experiencing motor fluctuations with at least two cumulative hours of daily "OFF" -time during the waking period, which is measured on at least two consecutive days
  • History of anti-parkinsonian treatment with sufficient doses of levodopa
  • Stable, well-controlled concomitant disorders that would not contraindicate general anesthesia or stereotactic neurosurgery
  • No abnormalities on baseline brain MRI
  • Insufficient control of PD symptoms or intolerable side effects with optimized oral PD therapy
  • Montreal Cognitive Assessment (MOCA) score ≥ 26
  • Willing to fully comply with all study procedures and requirements of the trial
  • No surgery for PD or been treated with neuroleptics in the past 6 months except low-dose quetiapine fumarate or clozapine
  • No significant further improvement with physical therapy/rehabilitation

Exclusion Criteria:

  • Mild cognitive impairment of dementia (MOCA score < 26)
  • The extent or severity of the disease is not measurable
  • Severe dyskinesia in the "OFF" or "ON" states (violent dyskinesias, incompatible with any normal motor task)
  • Pre-existing medical conditions such as bleeding disorders, septicemia, major cardiovascular, cerebrovascular or psychiatric disease
  • Any current or relevant previous history of serious, severe or unstable physical or psychiatric illness or medical disorder that may make the participant unlikely to fully complete the study (depression, anxiety, cognitive impairment or impulse control disorder)
  • Clinically significant abnormal hematologic evaluation (blood count, partial thromboplastin time (PTT)), blood chemistry (glucose, blood urea nitrogen (BUN), creatinine, electrolytes), liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGTP), total protein, bilirubin)
  • Any active infectious disease of any nature, including clinically active viral infections (seropositive for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Syphilis
  • Severe obesity
  • Previous intracranial surgery, including deep-brain stimulation
  • History of seizures
  • Substance abuse (recent history of alcohol abuse or other drugs such as barbiturates, cannabinoids and amphetamines)
  • Use of anti-platelet agents or other anti-coagulants
  • Signs of any malignant disease
  • Any use of immunosuppressive drugs
  • Enrollment in other investigational drug trial or has completed any trial within the last 3 months
  • Patients that cannot undergo MRI or PET scanning (i.e. patients with implanted pacemakers)
  • Patients unable to travel to the PET scanning center
  • Any other condition which clinician regards as making patient unsuitable for trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02452723


Contacts
Contact: Mary Hayek, BSc 613 9035 7325 mary.hayek@florey.edu.au

Locations
Australia, Victoria
Dept of Neurology, The Royal Melbourne Hospital Recruiting
Melbourne, Victoria, Australia, 3050
Sponsors and Collaborators
Cyto Therapeutics Pty Limited
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cyto Therapeutics Pty Limited
ClinicalTrials.gov Identifier: NCT02452723     History of Changes
Other Study ID Numbers: ISC-hpNSC
First Submitted: May 18, 2015
First Posted: May 25, 2015
Last Update Posted: August 22, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases